Stocks · News reference

8-K filing — Xeris Biopharma Holdings, Inc. (XERS)

Jul 17, 2026, 8:20 PMSEC EDGAR

Filed: 2026-07-17 AccNo: 0001867096-26-000055 Size: 173 KB Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 20, 2026, 3:35 PMBenzinga Newsdesk
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.
Read original at benzinga
XERS
BenzingaAug 6, 2026, 3:08 PMBenzinga Newsdesk
Xeris Biopharma shares are trading lower after the company reported mixed Q2 financial results.
Read original at benzinga
XERS
BenzingaAug 6, 2026, 1:31 PMBenzinga Newsdesk
UPDATE: Xeris Biopharma Holdings Q2 Adj. EPS $0.00, Inline
Read original at benzinga
XERS
SEC EDGARAug 6, 2026, 11:12 AMSEC EDGAR
8-K filing — Xeris Biopharma Holdings, Inc. (XERS)
Filed: 2026-08-06 AccNo: 0001867096-26-000063 Size: 334 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
XERS